Generex Biotechnology Corp – Strategy, SWOT and Corporate Finance Report

Generex Biotechnology Corp – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360Ëš view of the company.

Generex Biotechnology Corp (Generex) carries out the research, development and commercialization of drug delivery systems and technologies. It developed a proprietary platform technology to deliver drugs into the human body through the oral cavity. The company’s proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using its proprietary RapidMist device. Generex through its subsidiary, Antigen Express, has expanded its focus to include immunomedicines incorporating proprietary vaccine formulations for the treatment of infectious, malignant, allergic, and autoimmune diseases. Generex is headquartered in Miramar, Florida, the US.

Scope

Detailed information on Generex Biotechnology Corp required for business and competitor intelligence needs

A study of the major internal and external factors affecting Generex Biotechnology Corp in the form of a SWOT analysis

An in-depth view of the business model of Generex Biotechnology Corp including a breakdown and examination of key business segments

News about Generex Biotechnology Corp, such as business expansion, restructuring, and contract wins

Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

Gain understanding of Generex Biotechnology Corp and the factors that influence its strategies.

Track strategic initiatives of the company and latest corporate news and actions.

Assess Generex Biotechnology Corp as a prospective partner, vendor or supplier.

Support sales activities by understanding your customers' businesses better.

Stay up to date on Generex Biotechnology Corps business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

Sernova Corp

Novo Nordisk AS

Novavax Inc

Merck & Co Inc

MedImmune, Inc.

GlaxoSmithKline Plc

GeneNews Ltd

Eli Lilly and Co

Aptose Biosciences Inc

Apotex Inc

Ambrilia Biopharma Inc

Table of Contents

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1 - About the Company 6

Generex Biotechnology Corp - Key Facts 6

Generex Biotechnology Corp - Key Employees 7

Generex Biotechnology Corp - Key Employee Biographies 8

Generex Biotechnology Corp - Major Products and Services 9

Generex Biotechnology Corp - History 10

Generex Biotechnology Corp - Company Statement 13

Generex Biotechnology Corp - Locations And Subsidiaries 15

Head Office 15

Other Locations & Subsidiaries 15

Section 2 Company Analysis 16

Company Overview 16

Generex Biotechnology Corp - Business Description 17

Generex Biotechnology Corp - SWOT Analysis 18

SWOT Analysis - Overview 18

Generex Biotechnology Corp - Strengths 18

Generex Biotechnology Corp - Weaknesses 19

Generex Biotechnology Corp - Opportunities 20

Generex Biotechnology Corp - Threats 21

Generex Biotechnology Corp - Key Competitors 22

Section 3 Company Financial Ratios 23

Financial Ratios - Capital Market Ratios 23

Financial Ratios - Annual Ratios 24

Performance Chart 26

Financial Performance 26

Financial Ratios - Interim Ratios 27

Financial Ratios - Ratio Charts 28

Section 4 Company’s Lifesciences Financial Deals and Alliances 29

Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 29

Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 30

Generex Biotechnology Corp, Recent Deals Summary 31

Section 5 Company’s Recent Developments 32

Nov 29, 2018: Generex to acquire 51% stake in Olaregen Therapeutix 32

Nov 15, 2018: Generex announces appointment of executive management team 33

Oct 29, 2018: Generex Biotechnology Announces IND Filing for a Phase II Clinical Trial of AE37 in Combination with Pembrolizumab (Keytruda ) for the Treatment of Triple-Negative Breast Cancer 35

Oct 29, 2018: Generex Biotechnology Announces IND Filing for a Phase II Clinical Trial of AE37 in Combination with Pembrolizumab (Keytruda ) for the Treatment of Triple-Negative Breast Cancer 37

Oct 17, 2018: Generex Announces Launch of NuGenerex Distribution Solutions 39

Oct 17, 2018: Generex Announces Launch of NuGenerex Distribution Solutions 40

Oct 17, 2018: Generex Announces Launch of NuGenerex Distribution Solutions 41

Oct 12, 2018: Generex announces Anthony S. Crisci, Esq., CPA as general manager, chief compliance officer and corporate counsel of its new, wholly-owned subsidiary, NuGenerex distribution solutions 42

Oct 05, 2018: Generex Biotechnology Provides Update on AE37 Immuno-Therapeutic Clinical Development Program 43

Oct 05, 2018: Generex Biotechnology Provides Update on AE37 Immuno-Therapeutic Clinical Development Program 46

Section 6 Appendix 49

Methodology 49

Ratio Definitions 49

About GlobalData 53

Contact Us 53

Disclaimer 53

List of Tables

List of Tables

Generex Biotechnology Corp, Key Facts 6

Generex Biotechnology Corp, Key Employees 7

Generex Biotechnology Corp, Key Employee Biographies 8

Generex Biotechnology Corp, Major Products and Services 9

Generex Biotechnology Corp, History 10

Generex Biotechnology Corp, Subsidiaries 15

Generex Biotechnology Corp, Key Competitors 22

Generex Biotechnology Corp, Ratios based on current share price 23

Generex Biotechnology Corp, Annual Ratios 24

Generex Biotechnology Corp, Annual Ratios (Cont…1) 25

Generex Biotechnology Corp, Interim Ratios 27

Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 29

Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 30

Generex Biotechnology Corp, Recent Deals Summary 31

Currency Codes 49

Capital Market Ratios 49

Equity Ratios 50

Profitability Ratios 50

Cost Ratios 51

Liquidity Ratios 51

Leverage Ratios 52

Efficiency Ratios 52

List of Figures

List of Figures

Generex Biotechnology Corp, Performance Chart (2014 – 2018) 26

Generex Biotechnology Corp, Ratio Charts 28

Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 29

Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 30

    Pricing

Discounts available for multiple report purchases.

reportstore@marketline.com
+44 (0) 161 359 5817

Saved reports